Borzi, C.; Galli, G.; Ganzinelli, M.; Signorelli, D.; Vernieri, C.; Garassino, M.C.; Sozzi, G.; Moro, M.
Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. Pharmaceuticals 2020, 13, 385.
https://doi.org/10.3390/ph13110385
AMA Style
Borzi C, Galli G, Ganzinelli M, Signorelli D, Vernieri C, Garassino MC, Sozzi G, Moro M.
Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. Pharmaceuticals. 2020; 13(11):385.
https://doi.org/10.3390/ph13110385
Chicago/Turabian Style
Borzi, Cristina, Giulia Galli, Monica Ganzinelli, Diego Signorelli, Claudio Vernieri, Marina Chiara Garassino, Gabriella Sozzi, and Massimo Moro.
2020. "Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment" Pharmaceuticals 13, no. 11: 385.
https://doi.org/10.3390/ph13110385
APA Style
Borzi, C., Galli, G., Ganzinelli, M., Signorelli, D., Vernieri, C., Garassino, M. C., Sozzi, G., & Moro, M.
(2020). Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. Pharmaceuticals, 13(11), 385.
https://doi.org/10.3390/ph13110385
